Antiretroviral treatment strategies in resource-limited settings

Current HIV/AIDS Reports

Volumn 4, Issue 2, 2007, Pages 73-79

  Person, Anna K ^b   Ramadhani, Habib O ^b   Thielman, Nathan M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG MANUFACTURE; DRUG MONITORING; HEALTH CARE DELIVERY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIVER TOXICITY; META ANALYSIS; NEUROPATHY; PANCREATITIS; PRACTICE GUIDELINE; RASH; RISK FACTOR; SCALE UP; SOCIOECONOMICS; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MEDICALLY UNDERSERVED AREA; PATIENT COMPLIANCE; PUBLIC HEALTH PRACTICE;

EID: 34249331337     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-007-0011-z     Document Type: Article

References (42)

1. Walensky RP, Paltiel AD, Losina E, et al.: The survival benefits of AIDS treatment in the United States. J Infect Dis 2006, 194:11-19.
2. Freedberg KA, Losina E, Weinstein MC, et al.: The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001, 344:824-831.
3. Joint United Nations Programme on HIV/AIDS, World Heath Organization: AIDS Epidemic Update: December 2006. http://www.unaids.org/en/HIV_data/ epi2006/. Accessed January 31, 2007.
4. Joint United Nations Programme on HIV/AIDS: 2006 Report on the Global AIDS Epidemic: Executive Summary. Geneva: World Health Organization; 2006:1-24.
5. Feachem RG, Sabot OJ: An examination of the Global Fund at 5 years. Lancet 2006, 368:537-540.
6. World Health Organization: Progress on Global Access to HIV Antiretroviral Therapy: A Report on "3 by 5" and Beyond. Geneva: World Health Organization; 2006.
7. Joint United Nations Programme on HIV/AIDS: Scaling Up HIV Access to Prevention, Treatment, Care, and Support: The Next Steps. Geneva: Joint United Nations Programme on HIV/AIDS; 2006:1-48.
8. •• Severe P, Leger P, Charles M, et al.: Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005, 353:2325-2334. A study describing the feasibility of scaling up ART in a large number of patients in one of the world's most impoverished nations.
9. • Goldie SJ, Yazdanpanah Y, Losina E, et al.: Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. N Engl J Med 2006, 355:1141-1153. Using a computer-based simulation model, the authors demonstrate that trimethoprim-sulfamethoxazole and ART are cost-effective interventions in a resource-poor setting.
10. The World Bank: The World Bank Annual Report, 2003. http://www.worldbank.org/html/extpb/2003/download_ report.html. Accessed February 16, 2007.
11. Médecins Sans Frontières: Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries, edn 9. Geneva: Médecins Sans Frontières; 2006.
12. •• Weidle PJ, Wamai N, Solberg P, et al.: Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006, 368:1587-1594. A well-orchestrated, comprehensive antiretroviral distribution program administered through a home-based care program and demonstrating excellent antiretroviral adherence and corresponding virologic suppression in nearly 1000 patients.
13. Bwire R: Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment. Trop Med Int Health 2006, 11:1567-1575.
14. • Ferradini L, Jeanin, A, Pinoges, L, et al.: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006, 367:1335-1342. This paper describes excellent virologic, immunologic, and clinical outcomes of a large rural cohort organized by Médecins Sans Frontières in another resource-poor setting.
15. Holmberg SD, Palella FJ Jr, Lichtenstein KA, Havlir DV: The case for earlier treatment of HIV infection. Clin Infect Dis 2004, 39:1699-1704.
16. Hammer S, Saag, M, Schechter, M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006, 296:827-843.
17. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-related Disease in Adults and Children. http://www.who. int/hiv/pub/guidelines/hivstaging/en/index.html. Accessed January 31, 2007.
18. World Health Organization: Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-limited Settings: Toward Universal Access - Recommendations for a Public Health Approach. Geneva: World Health Organization; 2006.
19. World Health Organization: Scaling Up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach. 2003 revision. Geneva: World Health Organization; 2003.
20. Interim proposal for a WHO Staging System for HIV infection and disease. Wkly Epidemiol Rec 1990, 65:221-224.
21. •• Stringer JS, Zulu I, Levy J, et al.: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006, 296:782-793. Describing a scale-up program in Zambia adminstered through primary care sites, 16,198 patients were started on antretroviral therapy. Most mortality occurred early in the treatment course.
22. • Braitstein P, Brinkhof MW, Dabis F, et al.: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824. This analysis compared pooled data from multiple antretroviral treatment programs in low-income with those from high-income countries. The provision of free treatment in low-income settings was associated with lower mortality. Patients in these settings had higher mortality rates in the first few months of therapy, compared with their counterparts from high-income settings.
23. Idigbe EO, Adewole TA, Eisen G, et al.: Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005, 40:65-69.
24. Danel C, Moh R, Minga A, et al.: CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006, 367:1981-1989.
25. Hakim J: A structured treatment interruption strategy of 12 week cycles on and off ART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomisation within the DART trial [abstract THLB0207]. Paper presented at the XVI International AIDS Conference. Toronto, Canada; August 13-18, 2006.
26. Mills EJ, Nachega JB, Buchan I, et al.: Adherence to antiretroviral therapy in sub-Saharan Africa and North American: a mata-analysis. JAMA 2006, 296:679-690.
27. Nachega JB, Knowlton AR, Deluca A, et al.: Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults: a qualitative study. J Acquir Immune Defic Syndr 2006, 43(Suppl 1):S127-S133.
28. Nachega JB, Stein DM, Lehman DA, et al.: Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 2004, 20:1053-1056.
29. Crane JT, Kawuma A, Oyugi JH, et al.: The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS Behav 2006, 10:437-442.
30. Ramadhani H, Thielman N, Landman K, et al.: Predictors of maladherence among patients receiving fixed-dose combination stavudine/lamivudine/nevirapine in Northern Tanzania. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
31. Weiser S, Wolfe W, Bangsberg D, et al.: Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003, 34:281-288.
32. Laniece I, Ciss M, Desclaux A, et al.: Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003, 17(Suppl 3):S103-108.
33. Orrell C, Bangsberg DR, Badri M, Wood R: Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003, 17:1369-1375.
34. Gill CJ: Antiretroviral programme in rural Uganda. Lancet 2006, 368:1556-1557.
35. Calmy A, Ford N, Hirschel B, et al.: HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007, 44:128-134.
36. Bagchi S, Kempf MC, Westfall AO, et al.: Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis 2007, 44:135-138.
37. Schooley RT: Viral load testing in resource-limited settings. Clin Infect Dis 2007, 44:139-140.
38. Ramadhani H, Thielman N, Gao F, et al.: Predictors of virologic failure and HIV drug resistance among patients receiving fixed dose combination stavudine/lamivudine/nevirapine in northern Tanzania. Paper presented at the XVI International AIDS Conference. Toronto, Canada; August 13-18, 2006.
39. Spacek LA, Shihab HM, Kamya MR, et al.: Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006, 42:252-259.
40. Coetzee D, Hildebrand K, Boulle A, et al.: Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004, 18:887-895.
41. Wester CW, Kim S, Bussmann H, et al.: Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005, 40:336-343.
42. • DART Virology Group and Trial Team: Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006, 20:1391-1399. This paper describes first year data for the cohort within the DART trial randomized to receive zidovudine, lamivudine, and tenofovir. Seventy-two percent had plasma HIV RNA levels less than 400 copies/mL at 48 weeks.